跳至主要内容
临床试验/NCT01185145
NCT01185145Unknown2 期

A Phase II Study of Accelerated Partial Breast Radiotherapy With Either a Novel Breast Brachytherapy Technique - Mammosite or Intensity Modulated Radiotherapy

Rocky Mountain Cancer Centers12 个研究点 分布在 1 个国家目标入组 291 人开始时间: 2004年2月最近更新:
适应症

试验速览

阶段
2 期
入组人数
291
试验地点
12
主要终点
Overall Survival

研究概览

简要总结

Accelerated Partial Breast Irradiation by Mammosite and intensity modulated radiotherapy is safe and effective in patients with early stage breast cancer resected by lumpectomy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be a Tis, T1, N0, M0 AJC Classification
  • Have negative surgical margins (> or = 2 mm) after final surgery
  • Should have adequate skin spacing between balloon surface and surface the skin (> 7 mm)*
  • Patients with infiltrating lobular histologies should have breast MRI scanning as part of the initial staging to verify localized T1, or Tis disease
  • Multifocal findings (define as 2 or more breast quadrants) on MRI scanning should be further evaluated by ultrasound and, if necessary biopsy, to exclude multiquadrant disease.

排除标准

  • Be pregnant or breast-feeding
  • Have collagen-vascular disease
  • Inadequate surgical margins (< 2 mm)
  • Patients with malignant/suspicious calcifications

结局指标

主要结局

Overall Survival

时间窗: 2-15 years

Ipsilateral breast failure

时间窗: 2-15 years

Disease free survival

时间窗: 2-15 years

Cause specific survival

时间窗: 2-15 years

次要结局

  • Serious Adverse device-related Events(2-5 years)

研究者

申办方类型
Other

研究点 (12)

Loading locations...

相似试验